Corporate America (SPY, $289.34) Splurges $384 billion on Share Buybacks, While Capital Spending Remains Healthy
During the first half of 2018, S&P 500 companies spent $384 billion on buying back shares from shareholders, according to a Goldman Sachs report. That marks a whopping +48% increase since last year.
Apple went ahead with $45 billion worth of buybacks during the first half of 2018, which is triple the amount its spent during the same time period last year. Other companies with substantial share repurchase increases includes Amgen, Cisco, AbbVie and Oracle (as mentioned in the Goldman Sachs report).
For the full year 2018, share buyback authorizations among all US companies will exceed $1 trillion for the first time ever (according to Goldman Sachs projections). Share buybacks lower the number of outstanding shares of a company, thereby potentially pushing up the earnings per share metric – which in turn usually boost stock prices. Buybacks also indicate a firm’s healthy cash position, and therefore tend to bolster its stock price at least for the near-term.
Goldman Sachs estimated that buybacks are garnering the largest share of cash spending by S&P 500 firms - a departure from 19 out of the past 20 years where capital spending accounted for the biggest share.
Business spending still increased in the first half of 2018 – at 19% from last year – albeit at a slower rate compared to buybacks. Goldman Sachs predicts that capital spending is on pace for the fastest growth in at least 25 years.
AMGN in upward trend: 10-day moving average moved above 50-day moving average on October 07, 2025
The 10-day moving average for AMGN crossed bullishly above the 50-day moving average on October 07, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 17, 2025. You may want to consider a long position or call options on AMGN as a result. In of 71 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for AMGN just turned positive on September 30, 2025. Looking at past instances where AMGN's MACD turned positive, the stock continued to rise in of 49 cases over the following month. The odds of a continued upward trend are .
AMGN moved above its 50-day moving average on October 01, 2025 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where AMGN advanced for three days, in of 300 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 60 cases where AMGN's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AMGN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
AMGN broke above its upper Bollinger Band on October 01, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for AMGN entered a downward trend on September 30, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (21.645) is normal, around the industry mean (9.785). P/E Ratio (24.433) is within average values for comparable stocks, (24.212). Projected Growth (PEG Ratio) (0.969) is also within normal values, averaging (2.012). Dividend Yield (0.031) settles around the average of (0.028) among similar stocks. P/S Ratio (4.630) is also within normal values, averaging (3.527).
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 77, placing this stock slightly better than average.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. AMGN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of human therapeutic products based on cellular biology
Industry PharmaceuticalsMajor
Advertisement